The results were overwhelming: the GDM incidence was 6% in the group treated with 4000 mg myo-inositol/day, in comparison to 71% in the control group, the necessity of introducing insulin therapy being 3% in the group treated with myo-inositol compared to 21% in the control group, while neonatal hypoglycemia was 0% in the group treated with myo-inositol, compared to 26% in the control group. Here, INS is linked to gestational diabetes.